Kim George P, Grothey Axel
College of Medicine, Mayo Clinic.
Biologics. 2008 Jun;2(2):223-8. doi: 10.2147/btt.s1980.
The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.
人抗表皮生长因子受体（EGFR）单克隆抗体帕尼单抗代表了结直肠癌治疗的重大进展。靶向该受体的策略基于可靠的癌症生物学，证明其在结直肠癌发生过程中的关键作用。与它的前身西妥昔单抗不同，帕尼单抗是全人源的，因此降低了过敏反应的发生率。但是，在几项临床试验中，意外的毒性变得更加明显，引发了对帕尼单抗能否轻易取代西妥昔单抗的担忧。本文回顾了该药物的研发过程以及有助于我们理解其在结直肠癌治疗中最佳应用的关键临床试验。
